Smith Nicholas Conrad sold 23,170 shares of Alto Neuroscience, Inc. at $25.78 for −$597k on Sep 30, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
PRESIDENT AND CFO
PRESIDENT AND CFO
Filed Oct 1, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$597,290.16Shares × reported price
Shares traded
23,170Common Stock
Price per share
$25.78Reported price. Read footnotes for ranges.
% of reported position traded
48.15%This security and ownership context
Holdings after
24,946Direct
Trade date
Sep 30, 2026Sell
Filed
Oct 1, 2026, 9:33 PM ET2-day reporting delay
Accession
0002009130-26-000004Code S · Transaction 233626
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 48,116 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Related trades are temporarily unavailable. Open the SEC filing for the complete report, or reload this page.

ANRO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ANRO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +43%1w ago +47%1d ago +47%
Returns since7d −1.7%30d −8.9%90d180d1y

Footnotes in full

F1: This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F2: This price is a weighted average price. These securities were sold in multiple transactions at prices ranging from $26.5513 to $26.5902 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3: One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date. F4: 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.